Evidence map›Paper›PMID 41806329›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Real-Time In Vivo Visualization of Tumor-Associated Macrophage Reprogramming Using a Nitric Oxide-Activatable NIR-II Nanoinducer.

Qian Chen, Meng Li, Tuanwei Li, Chen Yang, Xiaohu Yang, Hongchao Yang, Yejun Zhang, Chunyan Li, Qiangbin Wang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qian ChenCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Meng LiCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Tuanwei LiCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Chen YangCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Xiaohu YangCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Hongchao YangCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Yejun ZhangCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Chunyan LiCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.ORCID https://orcid.org/0000-0002-1155-6050
Qiangbin WangCAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.

Funding

Key Research Program of Frontier Sciences, CAS ZDBS-LYSLH021National Key Research and Development Program of China 2024YFA1803402National Natural Science Foundation of China 22127808National Natural Science Foundation of China 22174158National Natural Science Foundation of China 22271308Natural Science Foundation of Jiangsu Province BE2022745Natural Science Foundation of Jiangsu Province BK20200254Natural Science Foundation of Jiangsu Province BK20210128Natural Science Foundation of Jiangsu Province BK20232046Natural Science Foundation of Jiangsu Province BK20240475Natural Science Foundation of Jiangsu Province BK20250383Science and Technology Project of Suzhou SJC2022001Science and Technology Project of Suzhou SZS201904
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME). They typically adopt an M2-like phenotype that promotes tumor progression by providing survival signals, suppressing anti-tumor immunity, and facilitating pre-metastatic niche formation. Reprogramming TAMs toward an anti-tumor phenotype has emerged as a promising therapeutic strategy, with the repolarization of M2-like TAMs into an M1-like phenotype being central to this approach. Here, a nitric oxide (NO)-activatable near-infrared-II (NIR-II) fluorescence/photoacoustic nanoinducer (I/E@M2pep) that selectively targets M2-like TAMs and reprograms them toward an M1-like phenotype, thereby enhancing anti-tumor efficacy is reported. In this construct, the M2pep peptide enables M2-like TAM targeting, IPI549 reprograms them toward an M1-like phenotype while inducing NO production, and the NO-activatable NIR-II probe (ETNO) allows for in vivo visualization of macrophage repolarization via NIR-II fluorescence/photoacoustic imaging. In a mouse breast cancer model, intravenous administration of I/E@M2pep produced a ratiometric NIR-II photoacoustic signal change that correlated with M2-to-M1 repolarization. Furthermore, combining this nanoinducer with a CD47 monoclonal antibody markedly enhanced anti-tumor immunity through M1 macrophage-mediated tumor killing and TME remodeling. This work presents an effective in vivo strategy that simultaneously facilitates and visualizes TAM repolarization, holding promise for broader applications in studying tumor initiation, metastasis, and treatment response.

Indexed as

Cellular ReprogrammingNitric OxideTumor-Associated MacrophagesTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMicePhotoacoustic TechniquesNitric OxideNIR‐II windowratiometric imagingtumor‐associated macrophage reprogrammingtumor microenvironment

Identifiers

PMID41806329
PMCPMC13205585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.